Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced β-TrCP degradation
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced β-TrCP degradation
Authors
Keywords
-
Journal
ONCOGENE
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-07-17
DOI
10.1038/s41388-019-0877-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy
- (2019) Yue Song et al. Immunotherapy
- The next generation of immunotherapy: keeping lung cancer in check
- (2017) Ashwin Somasundaram et al. Journal of Hematology & Oncology
- Cancer Immunotherapy: Whence and Whither
- (2017) Peter J. Stambrook et al. MOLECULAR CANCER RESEARCH
- PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
- (2017) Sydney R. Gordon et al. NATURE
- The SCF β-TRCP E3 ubiquitin ligase complex targets Lipin1 for ubiquitination and degradation to promote hepatic lipogenesis
- (2017) Kouhei Shimizu et al. Science Signaling
- The SCF β-TRCP E3 ubiquitin ligase complex targets Lipin1 for ubiquitination and degradation to promote hepatic lipogenesis
- (2017) Kouhei Shimizu et al. Science Signaling
- Combination immunotherapy: a road map
- (2017) Patrick A. Ott et al. Journal for ImmunoTherapy of Cancer
- Deubiquitination and Stabilization of PD-L1 by CSN5
- (2016) Seung-Oe Lim et al. CANCER CELL
- Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment
- (2016) Puyu Shi et al. CANCER LETTERS
- Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity
- (2016) Laurent Beziaud et al. CANCER RESEARCH
- Anti-PD-L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma
- (2016) Yukiyoshi Hirayama et al. CANCER SCIENCE
- Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non–small cell lung cancer
- (2016) Kazuhiko Shien et al. LUNG CANCER
- Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
- (2016) Chia-Wei Li et al. Nature Communications
- Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers
- (2016) E. C. Moore et al. Cancer Immunology Research
- Evolving Perspectives of mTOR Complexes in Immunity and Transplantation
- (2015) D. Fantus et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K/Akt signaling in human lung cancer cells
- (2015) Weilong Yao et al. CANCER LETTERS
- Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer
- (2015) Kristin J. Lastwika et al. CANCER RESEARCH
- mTOR Complex 2 Stabilizes Mcl-1 Protein by Suppressing Its Glycogen Synthase Kinase 3-Dependent and SCF-FBXW7-Mediated Degradation
- (2015) Junghui Koo et al. MOLECULAR AND CELLULAR BIOLOGY
- Maintaining Glycogen Synthase Kinase-3 Activity Is Critical for mTOR Kinase Inhibitors to Inhibit Cancer Cell Growth
- (2014) J. Koo et al. CANCER RESEARCH
- mTOR signaling, Tregs and immune modulation
- (2014) Nicole M Chapman et al. Immunotherapy
- Blockade of mTOR Signaling via Rapamycin Combined with Immunotherapy Augments Antiglioma Cytotoxic and Memory T-Cell Functions
- (2014) Y. Mineharu et al. MOLECULAR CANCER THERAPEUTICS
- mTOR inhibition improves immune function in the elderly
- (2014) J. B. Mannick et al. Science Translational Medicine
- mTOR kinase inhibitors as potential cancer therapeutic drugs
- (2013) Shi-Yong Sun CANCER LETTERS
- mTOR Inhibition Improves Antitumor Effects of Vaccination with Antigen-Encoding RNA
- (2013) M. Diken et al. Cancer Immunology Research
- Inhibition of Mechanistic Target of Rapamycin Promotes Dendritic Cell Activation and Enhances Therapeutic Autologous Vaccination in Mice
- (2012) E. Amiel et al. JOURNAL OF IMMUNOLOGY
- TNF-α and TGF-β Counter-Regulate PD-L1 Expression on Monocytes in Systemic Lupus Erythematosus
- (2012) Jing-Ni Ou et al. Scientific Reports
- Myxoma virus combined with rapamycin treatment enhances adoptive T cell therapy for murine melanoma brain tumors
- (2011) Diana L. Thomas et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Targeting the mTOR kinase domain: the second generation of mTOR inhibitors
- (2011) Yan-Jie Zhang et al. DRUG DISCOVERY TODAY
- Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy
- (2011) Seth A. Wander et al. JOURNAL OF CLINICAL INVESTIGATION
- c-Jun NH2-terminal kinase-dependent upregulation of DR5 mediates cooperative induction of apoptosis by perifosine and TRAIL
- (2011) Lei Fu et al. Molecular Cancer
- DEPTOR, an mTOR Inhibitor, Is a Physiological Substrate of SCFβTrCP E3 Ubiquitin Ligase and Regulates Survival and Autophagy
- (2011) Yongchao Zhao et al. MOLECULAR CELL
- mTOR Generates an Auto-Amplification Loop by Triggering the βTrCP- and CK1α-Dependent Degradation of DEPTOR
- (2011) Shanshan Duan et al. MOLECULAR CELL
- mTOR Drives Its Own Activation via SCFβTrCP-Dependent Degradation of the mTOR Inhibitor DEPTOR
- (2011) Daming Gao et al. MOLECULAR CELL
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
- (2010) D. M. Benson et al. BLOOD
- The role of mTOR in memory CD8+ T-cell differentiation
- (2010) Koichi Araki et al. IMMUNOLOGICAL REVIEWS
- Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy
- (2010) C A Sparks et al. ONCOGENE
- A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer
- (2009) Robert J. Amato et al. CANCER
- mTOR regulates memory CD8 T-cell differentiation
- (2009) Koichi Araki et al. NATURE
- Enhancing Mammalian Target of Rapamycin (mTOR)-Targeted Cancer Therapy by Preventing mTOR/Raptor Inhibition-Initiated, mTOR/Rictor-Independent Akt Activation
- (2008) X. Wang et al. CANCER RESEARCH
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started